|
Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)
F. Cappuzzo – ECCO/ESMO 2009 |
 Access webcast
|
|
Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial
E. Van Cutsen – ECOO/ESMO 2009 |
Access webcast
|
|
Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
J.J. Vredenburgh – ECCO/ESMO 2009 |
Access webcast
|
|
Bevacizumab plus IFN: delivering clinical benefit in mRCC
C. Porta – ECCO/ESMO 2009 (Roche Satellite Symposium) |
| Access webcast |
|
Moving beyond convention: anti-angiogenic therapy in cancer (NSCLC)
F. Griesinger – ECCO/ESMO 2009 (Roche Satellite Symposium) |
|
Access webcast |
|
Note: Links to external websites contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.
Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. |